Skip to main content

Pancreatic stone protein for early mortality prediction in COVID-19 patients

Coronavirus disease 2019 (COVID-19) pandemic is straining health care systems since December 2019 [1]. Tools to identify patients at risk of adverse outcome could optimize resource allocation.

Pancreatic stone protein (PSP) is a novel biomarker for infection and sepsis with promising results in various clinical settings [2]. A meta-analysis showed that PSP performed better than C-reactive protein (CRP) and procalcitonin for detecting infection among hospitalized patients, and that the combination of PSP and CRP further enhanced its accuracy [3]. Recently, serial measurement of PSP in patients admitted to the intensive care unit (ICU) allowed early detection of sepsis [4]. In a small case series, PSP daily monitoring was suggested as a marker of sepsis in critically ill COVID-19 patients [5].

In this prospective cohort study of COVID-19 patients in the emergency department (ED) of a teaching hospital in Switzerland, we assessed the accuracy of bedside clinical severity scores (Quick Sepsis-related Organ Failure Assessment (qSOFA) and CRB-65), PSP and CRP, which is associated with severity and mortality in COVID-19 [6], at clinical presentation for 7-day mortality and separately, ICU admission. Consecutive patients (≥ 18 years old) with symptoms of acute lower respiratory tract infection, were prospectively included in case of reverse-transcription PCR-confirmed COVID-19.

PSP was retrospectively measured in − 80° stored plasma collected in the ED (nanofluidic point-of-care immunoassay; abioSCOPE®, Abionic SA, Epalinges, Switzerland). CRP plasma concentration was determined upon admission via routine testing (immunoturbidimetrics determination; Cobas 8000 platform; Roche Diagnostics, Basel, Switzerland).

The predictive accuracy of clinical scores and host biomarkers was defined by the area under the receiver-operating characteristic curve (AUROC). Optimal cut-offs for sensitivity and specificity were determined using the Youden index. The combinatorial models were compared using the DeLong method.

All analyses were performed with STATA (version 15.0, Stata Corp, College Station, TX, USA) and R Core Team (2021). The Ethics Committee of the Vaud canton approved the study (CER-VD 2019-02283) and all patients gave their written informed consent.

Of the 173 patients included, 12 (6.9%) died (7 had limitations of life-sustaining treatment precluding ICU admission) and 37 (21.6%) were admitted to the ICU by day 7 (Table 1).The median time to death was 2.0 days (IQR 1.0, 3.5). The predicting accuracy of CRB-65 (AUROC 0.87; 95% CI 0.79–0.95), CRP (AUROC 0.83; 0.79–0.93) and PSP (AUROC 0.83; 0.74–0.92) for 7-day mortality were excellent and did not differ significantly, while the performance of qSOFA was lower compared to CRB-65 (p = 0.002; Fig. 1a). Figure 1b shows their optimal cut-offs for sensitivity and specificity, which had an excellent negative predictive value and a poor positive predictive value.

Table 1 Characteristics of study participants at inclusion in the emergency department according to 7-day mortality
Fig. 1
figure1

Accuracy and performance of biomarkers and clinical scores in patients with COVID-19 for 7-day mortality. A Nonparametric ROC curves were generated and AUROCs were plotted to illustrate the ability of bedside clinical scores and biomarkers to discriminate for 7-day mortality. B Sensitivity and specificity for optimal cut-offs determined using the Youden index, as well as positive predictive value, negative predictive value, positive likelihood ratio and negative likelihood ratio for the bedside clinical scores and the biomarkers are also reported

The combination of CRB-65 with biomarkers performed better than the clinical score or biomarkers alone: (1) CRB-65 plus PSP: AUROC 0.95; 0.91–0.98; p = 0.011 versus PSP; p = 0.033 versus CRB-65; (2) CRB-65 plus CRP: AUROC 0.96; 0.92–1.00; p = 0.017 versus CRP; p = 0.012 versus CRB-65 (Fig. 1a). Combination of PSP and CRP did not perform better than biomarkers or clinical scores alone.

CRP predicted 7-day ICU admission better than PSP (AUROC 0.74; 0.66–0.83 versus; 0.51; 0.41–0.61; p < 0.001).

The main limitations of our study are its monocentric design and the small number of patient meeting primary outcome.

CRB-65, CRP and PSP in the ED have an excellent accuracy to rule out early mortality in COVID-19. Combining CRB-65 and either biomarker improved their prognostic accuracy. As reported for sepsis, PSP appears to be a good biomarker to exclude short term risk of death [2], but not to exclude ICU admission in the context of COVID-19, suggesting different pathophysiological pathways for end-organ damage. Further research is needed to determine the clinical significance of PSP in the context of COVID-19 and its potential role as triage tool.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

COVID-19:

Coronavirus disease 2019

PSP:

Pancreatic stone protein

CRP:

C-reactive protein

ICU:

Intensive care unit

qSOFA:

Quick Sequential Organ Failure Assessment

AUROC:

Area under the receiver-operating characteristic curve

IQR:

Interquartile range

References

  1. 1.

    Emanuel EJ, Persad G, Upshur R, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049–55.

    Article  Google Scholar 

  2. 2.

    Eggimann P, Que Y-A, Rebeaud F. Measurement of pancreatic stone protein in the identification and management of sepsis. Biomark Med. 2019;13(2):135–45.

    CAS  Article  Google Scholar 

  3. 3.

    Prazak J, Irincheeva I, Llewelyn MJ, et al. Accuracy of pancreatic stone protein for the diagnosis of infection in hospitalized adults: a systematic review and individual patient level meta-analysis. Crit Care. 2021;25(1):182.

    Article  Google Scholar 

  4. 4.

    Pugin J, Daix T, Pagani J-L, et al. Serial measurement of pancreatic stone protein for the early detection of sepsis in intensive care unit patients: a prospective multicentric study. Critical Care. 2021;25(1):151.

  5. 5.

    Potential role of Pancreatic Stone Protein (PSP) as early marker of bacterial infection in COVID-19 patients [Internet]. [cited 2021 Jun 18];Available from: https://npselearning.it/img/38-vicenza/pdf/36.pdf.

  6. 6.

    Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19—a systematic review. Life Sci. 2020;254:117788.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank all the patients who accepted to participate and make this study possible. We thank Professor Carron, head of the emergency department, who supported the study. We thank all health care workers of the Emergency Department, Internal Medicine Ward, Infectious Disease Service, and Intensive Care Unit of the University Hospital of Lausanne, who managed patients with COVID-19. We thank Siméon Schaad, Luca Bosso, and Tanguy Espejo for helping in recruiting patients in the emergency department.

Funding

This work was supported in part by an academic award of the Leenaards Foundation (to NBB) and by the Foundation of Lausanne University Hospital (to NBB); Abionic SA supported the work by providing free of charge the abioSCOPE® and reactant for PSP dosing. The funding bodies had no role in the design of the study, in the collection, analysis and interpretation of data, and in writing the manuscript.

Author information

Affiliations

Authors

Contributions

NBB, OH, TB and MVS were involved in the study conception, study design, data analysis, data interpretation, and manuscript writing. MJBV and HGD were involved for the acquisition of the data and critical review of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Mathias Van Singer.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Human Research Ethics Committee of the Vaud canton (CER-VD 2019-02283) and all patients signed an informed consent form.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no relevant conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Van Singer, M., Brahier, T., Brochu Vez, MJ. et al. Pancreatic stone protein for early mortality prediction in COVID-19 patients. Crit Care 25, 267 (2021). https://doi.org/10.1186/s13054-021-03704-4

Download citation